EnChannel Medical Secures $82.2M in Series B Funding to Enhance Atrial Fibrillation Treatment Innovations

EnChannel Medical Raises $82.2 Million in Series B Financing



EnChannel Medical, a pioneering company in the field of cardiac electrophysiology based in Guangzhou, China, has announced a significant milestone in its financial journey. The company has successfully raised $82.2 million (or 600 million RMB) through an oversubscribed Series B financing round. This round was co-led by Dragonball Capital and existing investor Lilly Asia Ventures (LAV), with the ongoing support of Lapam Capital.

This financing marks one of the most substantial private investments within China's medical device sector since 2023, underlining the strong interest in EnChannel Medical's innovative approaches. In August 2023, the company had completed its Series A round, securing $27.8 million (195 million RMB), which set a robust foundation for its current success.

The funds raised in this latest Series B round are intended to accelerate the development of EnChannel’s advanced technologies and to facilitate clinical registration trials, not just in China but also internationally. According to Jun Feng, CEO of EnChannel Medical, the company’s platform is a game-changer, integrating full-chamber action potential mapping with pulsed-field ablation. This state-of-the-art solution aims to address the long-standing unmet needs for patients suffering from atrial fibrillation (AF).

Significance of the Funding


During an address following the announcement, Jun Feng expressed gratitude for the robust support received from both new and previous investors. He mentioned that early clinical data from ongoing studies has been promising, with key results presented at the Heart Rhythm Society Meeting, held on April 24-27 in San Diego. This notable event showcased advancements and discussions around heart rhythm disorders, where EnChannel presented its innovative findings.

Founded in 2020, EnChannel's mission has always been clear: to innovate within the complexities of cardiac electrophysiology. The company is led by a team of experienced professionals well-versed in both US and Chinese markets. Their focus is to develop a unified platform that integrates various technological advancements, such as magnetic-impedance navigation, intracardiac echocardiography, and the novel full-chamber 5D action-potential mapping feature. Such innovations will assist healthcare providers in offering safer and more personalized treatment plans for patients experiencing atrial fibrillation.

Additionally, EnChannel Medical is working on the DePolar® Mapping System and the NanoAblate® PFA System, which are currently in investigational stages and regulated for investigational use as per federal law in the United States. This focus on research and development is crucial in ensuring that the solutions they offer are not only effective but also adhere to rigorous guidelines.

A Vision for Global Expansion


Headquartered in Guangzhou, EnChannel also has an R&D subsidiary located in Irvine, California. This dual presence positions the company to enhance its innovation capabilities and push forward its goal of transforming atrial fibrillation care through data-driven and patient-specific solutions. As the healthcare landscape continues to evolve, EnChannel Medical's proactive steps towards developing comprehensive therapies could potentially revolutionize treatment options for AF patients worldwide.

For those interested in learning more about EnChannel Medical’s developments and ongoing projects, additional information can be found on their official website EnChannel.com or by following their updates on LinkedIn. The landscape of cardiac treatments is set to change dramatically, and EnChannel is at the forefront of this exciting journey.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.